Here's What Analysts Are Forecasting For Eris Lifesciences Limited (NSE:ERIS) After Its First-Quarter Results

Eris Lifesciences Limited (NSE:ERIS) shareholders are probably feeling a little disappointed, since its shares fell 3.3% to ₹1,355 in the week after its latest first-quarter results. It was a credible result overall, with revenues of ₹8.7b and statutory earnings per share of ₹45.26 both in line with analyst estimates, showing that Eris Lifesciences is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from Eris Lifesciences' ten analysts is for revenues of ₹35.3b in 2027. This would reflect a meaningful 9.9% increase on its revenue over the past 12 months. Statutory earnings per share are expected to dip 3.9% to ₹44.68 in the same period. In the lead-up to this report, the analysts had been modelling revenues of ₹35.9b and earnings per share (EPS) of ₹47.25 in 2027. The analysts seem to have become a little more negative on the business after the latest results, given the small dip in their earnings per share numbers for next year.

See our latest analysis for Eris Lifesciences

The consensus price target held steady at ₹1,661, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Eris Lifesciences, with the most bullish analyst valuing it at ₹1,780 and the most bearish at ₹1,435 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Eris Lifesciences is an easy business to forecast or the the analysts are all using similar assumptions.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Eris Lifesciences' revenue growth is expected to slow, with the forecast 13% annualised growth rate until the end of 2027 being well below the historical 21% p.a. growth over the last five years. Compare this to the 181 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 12% per year. Factoring in the forecast slowdown in growth, it looks like Eris Lifesciences is forecast to grow at about the same rate as the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Eris Lifesciences. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Eris Lifesciences going out to 2029, and you can see them free on our platform here..

Plus, you should also learn about the 2 warning signs we've spotted with Eris Lifesciences .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.